(NASDAQ: ASMB) Assembly Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Assembly Biosciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ASMB's revenue for 2024 to be $133,422,054, with the lowest ASMB revenue forecast at $133,422,054, and the highest ASMB revenue forecast at $133,422,054. On average, 1 Wall Street analysts forecast ASMB's revenue for 2025 to be $160,106,464, with the lowest ASMB revenue forecast at $160,106,464, and the highest ASMB revenue forecast at $160,106,464.
In 2026, ASMB is forecast to generate $149,741,445 in revenue, with the lowest revenue forecast at $149,741,445 and the highest revenue forecast at $149,741,445.